What Inuxair Treats: Main Uses and Benefits

Inuxair is a combination treatment commonly used across conditions involving chronic respiratory issues, primarily to help manage asthma and COPD (Chronic Obstructive Pulmonary Disease). The medication is applied in clinical settings that require additional symptomatic support for conditions presenting with chronic, episodic, or fluctuating symptom patterns.

It is relevant for managing symptoms related to physical discomfort and systemic imbalance, such as shortness of breath, tightness in the chest, and wheezing. The core purpose is long-term management to help maintain stability, especially during phases when symptoms become temporarily overwhelming or more noticeable. This provides support that helps ease the overall symptom burden and contributes to easing the overall symptom load during periods of heightened symptoms.

“The treatment may assist in maintaining functional stability for patients dealing with disruptive symptom manifestations.”

Quick Fact: Support for Symptoms of Breathlessness

Who Can and Cannot Use Inuxair?

The population eligibility for Inuxair is strictly defined by regulatory documents and depends on age, pre-existing health conditions, and physiological status.

Populations Allowed or Not Recommended

Absolute Contraindications

Inuxair must not be used in the following situations:

• Hypersensitivity: In patients with known allergy to the active substances (beclometasone dipropionate or formoterol fumarate dihydrate) or any excipients.
• Acute Episodes: It is contraindicated for treating an acute episode of bronchospasm or an acute exacerbation; it is not a rescue inhaler.

Use Requiring Caution

Patients with certain pre-existing conditions must use this medication under close monitoring, including those with specific cardiac arrhythmias, severe heart failure, thyrotoxicosis, diabetes mellitus, and untreated hypokalaemia. Regulatory information also notes that use is not established for patients with severe hepatic (liver) or renal (kidney) impairment due to a lack of data.

Interactions with other medicines and products

Inuxair contains budesonide (a corticosteroid) and formoterol (a long-acting beta-agonist), which are subject to specific interactions with other medicines and product categories. These interactions are categorized based on their mechanism and potential severity.

Pharmacokinetic and Pharmacodynamic Interactions

Important Interaction Constraints

Do Not Combine: Patients must not use Inuxair with other medicinal products containing a long-acting beta-agonist (LABA) for any reason, as this increases the risk of an overdose of the LABA component. The combination with strong CYP3A4 inhibitors should also be avoided unless clinically necessary, due to the increased systemic exposure to budesonide. In such cases, close monitoring for systemic corticosteroid effects is required.

Inuxair is a fixed-dose combination containing beclometasone dipropionate (BDP) and formoterol fumarate (FF), delivered as an extra-fine aerosol primarily targeting the respiratory tract, including the small airways.

BDP, a corticosteroid, acts as an agonist at intracellular glucocorticoid receptors (GRs). Upon binding, the activated GR complex translocates to the nucleus, modifying gene transcription. This modification involves the transrepression of pro-inflammatory genes encoding cytokines, chemokines, and adhesion molecules, and the transactivation of genes encoding anti-inflammatory proteins, such as annexin-A1. These intracellular consequences modulate the systemic inflammatory response in the lung tissue.

FF acts as a selective long-acting agonist at beta2-adrenergic receptors located on airway smooth muscle cells. Receptor binding activates the adenylyl cyclase enzyme via G s protein coupling, increasing intracellular cyclic adenosine monophosphate (cAMP) levels. Elevated cAMP concentration mediates the phosphorylation of downstream protein kinases, leading to smooth muscle relaxation. This cellular action results in bronchodilation, increasing the radius of the pulmonary airways and modulating system-level airflow dynamics.

How to Use Inuxair: Official Administration Guidelines

Inuxair (beclometasone dipropionate and formoterol fumarate dihydrate) is intended solely for oral inhalation as a long-term, continuous maintenance therapy for chronic obstructive airway diseases. The medicine is supplied as either a pressurised metered dose inhaler (pMDI) solution or an inhalation powder in devices like the NEXThaler. This inhaled route ensures the active ingredients are delivered directly to the respiratory tract.

Standard Dosing and Frequency

Usage patterns for the medicine require it to be inhaled twice daily—once in the morning and once in the evening—for consistent control. The dose is typically initiated at the lower end and should be titrated (adjusted) to the minimum level necessary to maintain effective stability. The maximum daily dose for maintenance therapy across both indications is restricted to four inhalations.

Special Administration Conditions

To ensure proper use and to minimize local residue, patients are directed to rinse their mouth or gargle with water, or brush their teeth, immediately after inhaling a dose. The pMDI device also requires a mandatory priming step before first use or after a period of non-use. While no dose adjustment is required for older adults, the higher strength (200 mu g/6 mu g) is generally not authorised for use in individuals under 18 years of age.

The information below summarizes the clinical research and evidence structure for the beclometasone and formoterol combination (Inuxair), relying on data from regulatory sources and peer-reviewed scientific studies. This summary focuses only on the scope and nature of the research, not on providing personal medical advice or instructions.

Research Evidence for Asthma Maintenance Treatment

Clinical research was studied for studies exploring long-term symptom patterns in persistent asthma. This evidence base primarily consists of randomized controlled trials (RCTs), which were applied in studies examining patient-reported experiences against other therapies, along with meta-analyses. Research was studied for changes in objective measures of lung function, such as FEV1. Studies also explored outcomes capturing phases of heightened symptom activity, focusing on the frequency and severity of asthma flare-ups. This research focused on adults and adolescents (typically 12 years and older) who had been previously receiving inhaled treatments but still had persistent symptoms.

Research Evidence for Chronic Obstructive Pulmonary Disease (COPD)

The evaluation of this combination in COPD is concentrated on studies examining the medicine in the context of long-term stability, particularly for patients with more functional limitations and a history of frequent, acute episodes. Long-term RCTs were central to this research. Research was evaluated in studies comparing the rate of COPD exacerbations between the combination and using the long-acting bronchodilator component alone. The research describes populations of adults who had compromised airflow and a documented history of acute episodes requiring extra medical attention.

Gaps and Areas of Uncertainty in the Research

One key limitation is that comparative evidence is lacking for a direct head-to-head comparison between this extra-fine formulation and all other non-extrafine ICS/LABA products available on the market, meaning comparative evidence is incomplete. Data for certain groups, such as children under 12 or populations not typically represented in large, controlled trials, remain insufficient. Research does not determine whether an individual will respond similarly to the group patterns described, and the results apply only to the populations studied.

Key Studies & References

1. Effectiveness and safety of extrafine beclomethasone/formoterol in patients with asthma or COPD: a systematic review and meta-analysis of randomized controlled trials

Common questions about Inuxair (FAQ)

Q: What are the storage requirements for Inuxair?

Official product information, based on regulatory labeling, states that Inuxair should typically be stored at room temperature.

Regulatory labeling indicates that the medication should be kept away from excessive moisture and direct heat, as improper storage may affect product quality. Specific storage details are always provided in the official patient information leaflet.

Q: Does taking Inuxair cause drowsiness or sleepiness?

Official regulatory documents indicate that Inuxair has been associated with certain side effects, such as dizziness or sleepiness, which are classified as effects on the central nervous system.

Because these effects may occur, regulatory documents typically advise exercising caution when performing activities that require alertness, such as driving or operating machinery. This information should be considered by all users.

Inuxair must be stored according to regulatory requirements to ensure its stability and effectiveness.

Storage Conditions

The medicine must be kept out of the sight and reach of children.

After the foil pouch is first opened, the product must not be stored above 25°C and must be used within 6 months of that date. Before the pouch is opened, the product should be stored in the original package.

Handling of the pressurised canister requires care: it must not be exposed to temperatures higher than 50°C, and it should not be pierced or burned, even when empty.

Disposal

Expired or unused Inuxair must not be thrown away via wastewater or household waste. Disposal must occur according to local requirements and environmental protection measures, typically by returning the medicine to a pharmacist or an authorized waste disposal service.